American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
Clemetson
Kenneth J
KJ
University of Berne, Theodor Kocher Institute, Freiestrasse 1, CH-3012 Berne, Switzerland. clemetson@tki.unibe.ch
D000755:Anemia, Sickle Cell / Q000188:drug therapy; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000187:drug effects; D001549:Benzamides / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D019013:CD40 Antigens / Q000187:drug effects; D004159:Diphenylamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006405:Hematology / Q000639:trends*; D006801:Humans; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors; D007951:Leukemia, Myeloid / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use; D000077157:Sorafenib
D000903:Antibiotics, Antineoplastic; D018951:Antigens, CD20; D001549:Benzamides; D001557:Benzenesulfonates; D019013:CD40 Antigens; D017730:Ki-1 Antigen; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; C506614:mirdametinib; D004159:Diphenylamine; D000077157:Sorafenib; D020930:MAP Kinase Kinase Kinases; D020123:Sirolimus